James S. Welsh
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
James S. Welsh has a total of 186 co-authors. Here are the top co-authors by number of shared publications:
- Seyed Mohammad Javad Mortazavi
Shiraz University of Medical Sciences
17 shared publications - Seyed Alireza Javadinia
Non-Communicable Diseases Research Center, Sabzevar University of Medical Sciences, Sabzevar, Iran
9 shared publications - Joseph John Bevelacqua
Bevelacqua Resources
6 shared publications - Babak PeyroShabany
Department of Internal Medicine, Sabzevar University of Medical Sciences, Sabzevar, Iran
5 shared publications - Danial Fazilat-Panah
Assistant Professor of Radiation Oncology, Cancer Research Center, Health Research Institute, Babol University of Medical Sciences, Babol, I.R. Iran
4 shared publications - Mansoureh Dehghani
Cancer Research Centre Mashhad University of Medical Sciences Mashhad Iran
4 shared publications
Latest Publications
- Open Access
- 18 October 2026
- Published by SAGE Publications in Dose-Response
- Vol. 24 (4)
Rethinking Annual Dose Limits: A Biologically Based Critique of Radiation Protection Standards
Annual dose limits provide a practical basis for radiation protection, but a calendar year is not necessarily a biologically meaningful interval. Cellular repair, adaptive responses, and dose-rate effects may alter outcomes when the same total dose is delivered in different patterns. Conversely, rapid repair of measurable damage does not establish the absence of delayed effects or justify higher permissible doses. We propose research into temporally resolved exposure metrics that could complement cumulative dose accounting. Any regulatory change would require evidence linking exposure patterns to relevant health outcomes.
- 18 October 2026
- Published by SAGE Publications in Dose-Response
- Vol. 24 (4)
Open AccessRethinking Annual Dose Limits: A Biologically Based Critique of Radiation Protection Standards
Annual dose limits provide a practical basis for radiation protection, but a calendar year is not necessarily a biologically meaningful interval. Cellular repair, adaptive responses, and dose-rate effects may alter outcomes when the same total dose is delivered in different patterns. Conversely, rapid repair of measurable damage does not establish the absence of delayed effects or justify higher permissible doses. We propose research into temporally resolved exposure metrics that could complement cumulative dose accounting. Any regulatory change would require evidence linking exposure patterns to relevant health outcomes.
- Open Access
- 10 October 2026
- Published by Brieflands in International Journal of Cancer Management
- Vol. 19 (1) , e175267
Prioritizing Chemotherapy in Total Neoadjuvant Therapy for Locally Advanced Rectal Cancer: A Policy Brief for Settings with Limited Timely Radiotherapy Access
- 10 October 2026
- Published by Brieflands in International Journal of Cancer Management
- Vol. 19 (1) , e175267
Open AccessPrioritizing Chemotherapy in Total Neoadjuvant Therapy for Locally Advanced Rectal Cancer: A Policy Brief for Settings with Limited Timely Radiotherapy Access
- 21 September 2026
- Published by Wolters Kluwer Health in American Journal of Clinical Oncology
Radiation-Induced Proctitis and Hemorrhagic Cystitis
Radiation therapy is a cornerstone in the management of pelvic and thoracic malignancies, but injury to surrounding normal tissue remains a clinically significant source of late morbidity despite advances in treatment delivery. Radiation-induced proctitis and hemorrhagic cystitis are consequential pelvic toxicities, typically presenting months to years after treatment with rectal bleeding, diarrhea, urgency, tenesmus, hematuria, and irritative lower urinary tract symptoms. Beyond the pelvis, radiation enteritis and pneumonitis represent important gastrointestinal and pulmonary complications that may similarly impair quality of life. Although severe toxicity has become less common with contemporary treatment planning, management remains challenging because of the chronic, multifactorial nature of radiation injury and limited high-quality randomized evidence. Treatment is generally individualized according to symptom severity, affected organ, and chronicity. Medical therapies include anti-inflammatory agents, antioxidants, and topical or intravesical treatments aimed at reducing inflammation and promoting mucosal healing. For chronic hemorrhagic disease, endoscopic interventions such as argon plasma coagulation, radiofrequency ablation, laser therapy, and cryotherapy target friable or telangiectatic lesions. In refractory cases, hyperbaric oxygen therapy (HBOT) has emerged as an important salvage modality by promoting angiogenesis, neovascularization, and tissue repair in irradiated tissue. Surgery is reserved for severe, refractory disease or complications, including fistula, obstruction, or life-threatening hemorrhage. This review examines contemporary management of radiation-induced proctitis and hemorrhagic cystitis, with comparative discussion of radiation enteritis and pneumonitis. We highlight organ-specific differences in pathophysiology, presentation, medical and endoscopic therapies, HBOT, and surgical intervention, emphasizing a stepwise approach to management.
- 21 September 2026
- Published by Wolters Kluwer Health in American Journal of Clinical Oncology
Radiation-Induced Proctitis and Hemorrhagic Cystitis
Radiation therapy is a cornerstone in the management of pelvic and thoracic malignancies, but injury to surrounding normal tissue remains a clinically significant source of late morbidity despite advances in treatment delivery. Radiation-induced proctitis and hemorrhagic cystitis are consequential pelvic toxicities, typically presenting months to years after treatment with rectal bleeding, diarrhea, urgency, tenesmus, hematuria, and irritative lower urinary tract symptoms. Beyond the pelvis, radiation enteritis and pneumonitis represent important gastrointestinal and pulmonary complications that may similarly impair quality of life. Although severe toxicity has become less common with contemporary treatment planning, management remains challenging because of the chronic, multifactorial nature of radiation injury and limited high-quality randomized evidence. Treatment is generally individualized according to symptom severity, affected organ, and chronicity. Medical therapies include anti-inflammatory agents, antioxidants, and topical or intravesical treatments aimed at reducing inflammation and promoting mucosal healing. For chronic hemorrhagic disease, endoscopic interventions such as argon plasma coagulation, radiofrequency ablation, laser therapy, and cryotherapy target friable or telangiectatic lesions. In refractory cases, hyperbaric oxygen therapy (HBOT) has emerged as an important salvage modality by promoting angiogenesis, neovascularization, and tissue repair in irradiated tissue. Surgery is reserved for severe, refractory disease or complications, including fistula, obstruction, or life-threatening hemorrhage. This review examines contemporary management of radiation-induced proctitis and hemorrhagic cystitis, with comparative discussion of radiation enteritis and pneumonitis. We highlight organ-specific differences in pathophysiology, presentation, medical and endoscopic therapies, HBOT, and surgical intervention, emphasizing a stepwise approach to management.
- Open Access
- 18 September 2026
- Published by Springer Nature in Cureus
- Vol. 18 (9)
Pulsed Low-Dose-Rate Radiotherapy (PLDR): A Comprehensive Review of Radiobiological Rationale and Clinical Applications in Modern Cancer Care
Pulsed low-dose-rate radiotherapy (PLDR) has emerged as a promising retreatment strategy that delivers radiation in a series of low-dose pulses, potentially increasing sublethal damage repair in normal tissues while exploiting low-dose hyper-radiosensitivity and impaired DNA repair mechanisms in tumor cells. This review synthesizes current evidence on PLDR by outlining its historical development, radiobiological foundations, and evolving clinical applications across tumor sites, with particular attention to re-irradiation settings. Preclinical studies suggest enhanced normal-tissue sparing and modulation of cellular responses under pulsed dose-rate conditions, supporting the mechanistic rationale for clinical use. Early clinical experience indicates favorable tolerability and potential therapeutic benefit in brain, spine, head and neck, breast, and pelvic malignancies, although these data are predominantly retrospective and heterogeneous. Despite these encouraging findings, major challenges remain, including limited prospective data, variation in dose-fractionation schemes, and incomplete understanding of long-term safety. Collectively, available evidence positions PLDR as a feasible and biologically grounded option for patients requiring re-irradiation, while underscoring the urgent need for standardized protocols and well-designed clinical trials to define its optimal use and long-term therapeutic value.
- 18 September 2026
- Published by Springer Nature in Cureus
- Vol. 18 (9)
Open AccessPulsed Low-Dose-Rate Radiotherapy (PLDR): A Comprehensive Review of Radiobiological Rationale and Clinical Applications in Modern Cancer Care
Pulsed low-dose-rate radiotherapy (PLDR) has emerged as a promising retreatment strategy that delivers radiation in a series of low-dose pulses, potentially increasing sublethal damage repair in normal tissues while exploiting low-dose hyper-radiosensitivity and impaired DNA repair mechanisms in tumor cells. This review synthesizes current evidence on PLDR by outlining its historical development, radiobiological foundations, and evolving clinical applications across tumor sites, with particular attention to re-irradiation settings. Preclinical studies suggest enhanced normal-tissue sparing and modulation of cellular responses under pulsed dose-rate conditions, supporting the mechanistic rationale for clinical use. Early clinical experience indicates favorable tolerability and potential therapeutic benefit in brain, spine, head and neck, breast, and pelvic malignancies, although these data are predominantly retrospective and heterogeneous. Despite these encouraging findings, major challenges remain, including limited prospective data, variation in dose-fractionation schemes, and incomplete understanding of long-term safety. Collectively, available evidence positions PLDR as a feasible and biologically grounded option for patients requiring re-irradiation, while underscoring the urgent need for standardized protocols and well-designed clinical trials to define its optimal use and long-term therapeutic value.
- Open Access
- 18 April 2026
- Published by SAGE Publications in Dose-Response
- Vol. 24 (2)
Society, Nuclear Energy and Radiological Protection - Beyond LNT
In a recent paper, Allison (Health Phys. 2024) proposed that a daily limit of 2 mGy will adequately protect the general public and radiation workers against any health-threatening effects of ionizing radiation. The 2 mGy/day limit, established at the 1934 Congress of Radiology for radiologists exposed to diagnostic X-rays, is over 500 times that currently recommended by ICRP for the general public. This illustrates the severe over-restrictiveness and irrationality of the present LNT-based system of radiological protection that is recommended by ICRP and NCRP and is legally implemented worldwide. To stimulate further discussion on developing a more rational “post-LNT” system, we indicate and briefly discuss some relevant publications, which also present arguments which could be helpful in managing radiation risk and in reducing public fear of nuclear radiation. Society should then become more willing to accept and appreciate the unique opportunities offered by nuclear technology, especially in health care and energy production.
- 18 April 2026
- Published by SAGE Publications in Dose-Response
- Vol. 24 (2)
Open AccessSociety, Nuclear Energy and Radiological Protection - Beyond LNT
In a recent paper, Allison (Health Phys. 2024) proposed that a daily limit of 2 mGy will adequately protect the general public and radiation workers against any health-threatening effects of ionizing radiation. The 2 mGy/day limit, established at the 1934 Congress of Radiology for radiologists exposed to diagnostic X-rays, is over 500 times that currently recommended by ICRP for the general public. This illustrates the severe over-restrictiveness and irrationality of the present LNT-based system of radiological protection that is recommended by ICRP and NCRP and is legally implemented worldwide. To stimulate further discussion on developing a more rational “post-LNT” system, we indicate and briefly discuss some relevant publications, which also present arguments which could be helpful in managing radiation risk and in reducing public fear of nuclear radiation. Society should then become more willing to accept and appreciate the unique opportunities offered by nuclear technology, especially in health care and energy production.
- 2 April 2026
- Published by Springer Nature in Supportive Care in Cancer
- Vol. 34 (4) , 401
Preventive effects of dexamethasone oral solution on radiation-induced mucositis in patients with head and neck cancer: a randomized, triple-blind, parallel-group trial
Purpose Radiation-induced oral mucositis is a frequent and debilitating complication of curative radiotherapy for head and neck cancer. This randomized, triple-blind, placebo-controlled, parallel-group trial evaluated whether a topical dexamethasone oral solution (0.5 mg/10 mL) used as a prophylactic mouthwash reduces the incidence and severity of radiation-induced oral mucositis. Methods Fifty-four patients with non-metastatic head and neck squamous cell carcinoma scheduled to receive ≥ 60 Gy radiotherapy were randomized 1:1 to dexamethasone mouthwash or placebo and instructed to gargle 10 mL four times daily during radiotherapy. The primary endpoint was the incidence and maximum severity of oral mucositis occurring during radiotherapy, defined as the highest grade recorded using the WHO Oral Toxicity Scale and NCI-CTCAE criteria v. 5. Secondary endpoints included patient-reported pain (VAS), dysphagia, treatment discontinuation, and mucositis status at 2 months. Fifty patients completed the study (25 per arm); four patients discontinued (reasons reported in Results). Results The dexamethasone group had significantly lower mucositis severity at all time points by WHO and CTCAE scales (all p < 0.01), a delayed peak severity (week 5 vs week 3), lower pain scores from weeks 4–7 (median VAS 0–3 versus 4–6; p < 0.01), and lower dysphagia at 2 months (32% vs 72%; p = 0.01). No grade 4 mucositis occurred in the dexamethasone arm; two grade 4 events occurred in placebo. There were no statistically significant differences in treatment discontinuation. Topical dexamethasone was well tolerated; no signal of treatment-related systemic steroid toxicity or increased oral infections was observed. Conclusion In this phase II study, prophylactic topical dexamethasone mouthwash reduced the severity and delayed the onset of radiation-induced oral mucositis and improved patient-reported pain. These findings are promising but require confirmation in larger multicenter trials with longer follow-up and formal patient-reported outcomes (e.g., EORTC QLQ-H&N35, OMAS) and comparison with guideline-recommended strategies such as photobiomodulation. Trial registration number Iranian Registry of Clinical Trials; trial registration number: IRCT20240525061893N1; date of registration: 21 July 2024.
- 2 April 2026
- Published by Springer Nature in Supportive Care in Cancer
- Vol. 34 (4) , 401
Preventive effects of dexamethasone oral solution on radiation-induced mucositis in patients with head and neck cancer: a randomized, triple-blind, parallel-group trial
Purpose Radiation-induced oral mucositis is a frequent and debilitating complication of curative radiotherapy for head and neck cancer. This randomized, triple-blind, placebo-controlled, parallel-group trial evaluated whether a topical dexamethasone oral solution (0.5 mg/10 mL) used as a prophylactic mouthwash reduces the incidence and severity of radiation-induced oral mucositis. Methods Fifty-four patients with non-metastatic head and neck squamous cell carcinoma scheduled to receive ≥ 60 Gy radiotherapy were randomized 1:1 to dexamethasone mouthwash or placebo and instructed to gargle 10 mL four times daily during radiotherapy. The primary endpoint was the incidence and maximum severity of oral mucositis occurring during radiotherapy, defined as the highest grade recorded using the WHO Oral Toxicity Scale and NCI-CTCAE criteria v. 5. Secondary endpoints included patient-reported pain (VAS), dysphagia, treatment discontinuation, and mucositis status at 2 months. Fifty patients completed the study (25 per arm); four patients discontinued (reasons reported in Results). Results The dexamethasone group had significantly lower mucositis severity at all time points by WHO and CTCAE scales (all p < 0.01), a delayed peak severity (week 5 vs week 3), lower pain scores from weeks 4–7 (median VAS 0–3 versus 4–6; p < 0.01), and lower dysphagia at 2 months (32% vs 72%; p = 0.01). No grade 4 mucositis occurred in the dexamethasone arm; two grade 4 events occurred in placebo. There were no statistically significant differences in treatment discontinuation. Topical dexamethasone was well tolerated; no signal of treatment-related systemic steroid toxicity or increased oral infections was observed. Conclusion In this phase II study, prophylactic topical dexamethasone mouthwash reduced the severity and delayed the onset of radiation-induced oral mucositis and improved patient-reported pain. These findings are promising but require confirmation in larger multicenter trials with longer follow-up and formal patient-reported outcomes (e.g., EORTC QLQ-H&N35, OMAS) and comparison with guideline-recommended strategies such as photobiomodulation. Trial registration number Iranian Registry of Clinical Trials; trial registration number: IRCT20240525061893N1; date of registration: 21 July 2024.
- Open Access
- 1 April 2026
- Published by SAGE Publications in Dose-Response
- Vol. 24 (2)
Does Radioactivity From Nuclear Power Plants Raise the Risk of Cancer? Harvard School of Public Health: Yes. Biology: No
- 1 April 2026
- Published by SAGE Publications in Dose-Response
- Vol. 24 (2)
Open AccessDoes Radioactivity From Nuclear Power Plants Raise the Risk of Cancer? Harvard School of Public Health: Yes. Biology: No
- Open Access
- 24 January 2026
- Published by SAGE Publications in Dose-Response
- Vol. 24 (1)
I-129 in Nuclear Waste: Much Ado About Nothing
Recent articles and news blogs have been written about nuclear waste management, specifically focusing on the alleged hazards of iodine-129. Here, we objectively review the specific details of iodine-129 as a radiation hazard. In contrast with the alarmist tone of these recent papers and news items, we conclude that iodine-129 is not nearly as concerning as has been projected. Rather, it appears to be a classic case of “much ado about nothing”.
- 24 January 2026
- Published by SAGE Publications in Dose-Response
- Vol. 24 (1)
Open AccessI-129 in Nuclear Waste: Much Ado About Nothing
Recent articles and news blogs have been written about nuclear waste management, specifically focusing on the alleged hazards of iodine-129. Here, we objectively review the specific details of iodine-129 as a radiation hazard. In contrast with the alarmist tone of these recent papers and news items, we conclude that iodine-129 is not nearly as concerning as has been projected. Rather, it appears to be a classic case of “much ado about nothing”.
- Open Access
- 1 January 2026
- Published by Salvia Medical Sciences Ltd in Journal of Biomedical Physics and Engineering
Beyond Physical Shielding: The Case for Biological Protection in Deep Space
- 1 January 2026
- Published by Salvia Medical Sciences Ltd in Journal of Biomedical Physics and Engineering
Open AccessBeyond Physical Shielding: The Case for Biological Protection in Deep Space
- Open Access
Daily Consumption of Apigenin Prevents Acute Lymphoma/Lymphoblastic Leukemia in Male C57BL/6J Mice Exposed to Space-like Radiation
Introduction: The work presented here is part of our study series aimed at investigating the countermeasure effectiveness of apigenin (AP) against both early and late effects of heavy silicon (28Si) on the same cohort of exposed male C57BL/6 mice. We previously reported the countermeasure of AP against 28Si-induced early effects of 28Si ions. This section focuses on the protective effects of AP on late effects, specifically on the induction of acute lymphoma/lymphoblastic leukemia. Method: Mice received a diet containing 20 mg/kg body weight of AP for five days before and after total-body irradiation with either 0 or 0.5 Gy of 260 MeV 28Si ions. They were divided into four groups based on AP intake and irradiation status. At one-week after irradiation, six mice from each group were euthanized to assess AP’s effectiveness against early inflammation (in the bone marrow and gut tissues) and gut dysbiosis. The remaining mice were monitored until approximately 770 days of age. Incidence rates were analyzed using Chi-Square tests, while survival data were evaluated with Kaplan–Meier plots and log-rank tests, setting significance at p ≤ 0.05. Results: At 770 days, survival rates were 37% for 28Si-exposed mice and 63% for those consuming AP, despite irradiation. There was a 2.57-fold increase in acute lymphoma/lymphoblastic leukemia incidence among 28Si-exposed mice not receiving AP compared to controls and AP-fed mice. Together with our previous report on the countermeasure activity of AP against early effects, these findings suggest that the gut–bone marrow axis plays an important role in 28Si-induced acute lymphoma/lymphoblastic leukemia. Conclusion: Our findings demonstrate that AP is an effective means of tackling the challenges posed by space radiation, and it has the potential to revolutionize protection in this critical area.
Open AccessDaily Consumption of Apigenin Prevents Acute Lymphoma/Lymphoblastic Leukemia in Male C57BL/6J Mice Exposed to Space-like Radiation
Introduction: The work presented here is part of our study series aimed at investigating the countermeasure effectiveness of apigenin (AP) against both early and late effects of heavy silicon (28Si) on the same cohort of exposed male C57BL/6 mice. We previously reported the countermeasure of AP against 28Si-induced early effects of 28Si ions. This section focuses on the protective effects of AP on late effects, specifically on the induction of acute lymphoma/lymphoblastic leukemia. Method: Mice received a diet containing 20 mg/kg body weight of AP for five days before and after total-body irradiation with either 0 or 0.5 Gy of 260 MeV 28Si ions. They were divided into four groups based on AP intake and irradiation status. At one-week after irradiation, six mice from each group were euthanized to assess AP’s effectiveness against early inflammation (in the bone marrow and gut tissues) and gut dysbiosis. The remaining mice were monitored until approximately 770 days of age. Incidence rates were analyzed using Chi-Square tests, while survival data were evaluated with Kaplan–Meier plots and log-rank tests, setting significance at p ≤ 0.05. Results: At 770 days, survival rates were 37% for 28Si-exposed mice and 63% for those consuming AP, despite irradiation. There was a 2.57-fold increase in acute lymphoma/lymphoblastic leukemia incidence among 28Si-exposed mice not receiving AP compared to controls and AP-fed mice. Together with our previous report on the countermeasure activity of AP against early effects, these findings suggest that the gut–bone marrow axis plays an important role in 28Si-induced acute lymphoma/lymphoblastic leukemia. Conclusion: Our findings demonstrate that AP is an effective means of tackling the challenges posed by space radiation, and it has the potential to revolutionize protection in this critical area.